Avaliação audiológica e monitoramento auditivo em pacientes com Hepatite C

• Ano de defesa: 2019
• Autor(a) principal: Lagreca, Lorena Carvalho Cavalcanti [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Hearing; Hearing Loss; Hepatitis C; Cochlea; Audição; Perda Auditiva; Hepatite C; Cóclea
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=8333610; https://repositorio.unifesp.br/handle/11600/59740

Hepatitis C virus (HCV) infection is one of the leading causes of chronic liver disease in the world and may be associated with hearing loss due to the disease or traditional treatment. Objective: To verify the occurrence of hearing impairment in patients with hepatitis C virus and the effect of antivirals, currently recommended by the Ministry of Health, on hearing. Method: The sample consisted of 27 individuals with hepatitis C virus, of both sexes and with an average age of 51 years. Individuals with conductive or mixed hearing loss and those with risk factors for hearing loss were excluded from the group. For the comparative study two groups were evaluated: the study group with 18 individuals with hepatitis C virus and a control group, composed of 18 individuals, volunteers, without hearing complaints and/or risk factors for hearing loss. For the study of the effect of drugs on hearing, the evaluation was performed in 16 patients, in two moments: before the use of direct acting antivirals and after the end of the treatment of three months. The audiological evaluation included the following procedures: anamnesis, external auditory canal inspection, pure tone audiometry, speech reception threshold, speech recognition index, acoustic immittance measures and transient and distortion product otoacoustic emissions. Results: 44.4% of patients with hepatitis C virus had sensorineural hearing loss and 44.4% had cochlear dysfunction; hearing loss was superior at the higher frequencies with main occurrence of hearing loss in individuals over 40 years (44.4%) and in males (66.7%); there was low occurrence of tinnitus and vertigo; only 51.9% of patients with hepatitis C virus had transient stimulus evoked otoacoustic emissions and 11.1% had distortion product evoked otoacoustic emissions; there was an association between the results of pure tone audiometry and transient stimulus evoked otoacoustic emissions (TEOAE) in patients with hepatitis C virus: higher occurrence of emissions in individuals with normal hearing (80%) and greater absence of emissions in individuals with hearing loss (83.3%); there was an association between the results of pure tone audiometry and distortion product evoked otoacoustic emissions (DPEOAE), with a higher occurrence of hearing loss in individuals without DPEOAE; hearing loss in the study group was higher than that found in the control group; there was no statistically significant difference between pre- and post-treatment evaluation results. Conclusion: Due to the high occurrence of hearing loss in patients with hepatitis C virus, audiological evaluation is recommended, especially in patients over 40 years. The treatment proposed recently by the Ministry of Health does not cause adverse effects on hearing function.